2024
Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
Valdez C, Sánchez-Zuno G, Osmani L, Ibrahim W, Galan A, Bacchiocchi A, Halaban R, Kulkarni R, Kang I, Bucala R, Tran T. Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma. Oncotarget 2024, 15: 507-520. PMID: 39028303, PMCID: PMC11259151, DOI: 10.18632/oncotarget.28615.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkers, TumorFemaleHistocompatibility Antigens Class IIHumansImmune Checkpoint InhibitorsIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMelanomaMiddle AgedMutationPrognosisRetrospective StudiesSkin NeoplasmsConceptsMacrophage migration inhibitory factorImmune checkpoint inhibitionD-dopachrome tautomeraseExpression of macrophage migration inhibitory factorDrivers of tumor progressionInflammatory cell markersPatient tumor samplesPatient survival outcomesMigration inhibitory factorStatistically significant differenceCheckpoint inhibitionImmune therapyPrognostic valueSurvival outcomesResistant melanomaGene expressionImproved survivalRetrospective studyInflammatory markersTumor progressionCell markersTumor samplesClinical evidenceMelanomaBulk RNA sequencingDigital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma
Su D, Schoenfeld D, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm D, Khan S, Halaban R, Kluger H, Olino K, Galan A, Clune J. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. Journal For ImmunoTherapy Of Cancer 2024, 12: e008646. PMID: 38519058, PMCID: PMC10961546, DOI: 10.1136/jitc-2023-008646.Peer-Reviewed Original ResearchConceptsCTLA-4 expression levelsCancer-associated fibroblastsAssociated with worse survivalExpression of immune checkpointsLAG-3 expressionDesmoplastic melanomaLymphoid aggregatesCTLA-4PD-1Immune checkpointsIntratumoral leukocytesLAG-3Tumor compartmentsWorse survivalCD20+B cellsIncreased expression of immune checkpointsProgrammed cell death protein 1Macrophage/monocyte markerSentinel lymph node positivityCell death protein 1Associated with poor prognosisLymph node positivityDense fibrous stromaPotential prognostic significanceCore of tumors
2023
Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas
Ly C, Blaha O, Wei W, Galan A, Kluger H, Ariyan S, Olino K, Clune J. Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. Frontiers In Oncology 2023, 12: 1077226. PMID: 36686728, PMCID: PMC9853390, DOI: 10.3389/fonc.2022.1077226.Peer-Reviewed Original ResearchMelanoma-specific mortalityElevated mitotic rateLymph node positivityMitoses/Mitotic rateT2 tumorsNode positivityThin melanomasSentinel lymph node positivityImportant prognostic factorSingle academic centerPrimary cutaneous melanomaLow mitotic ratePositive SLNNon-ulcerated lesionsSLN biopsyT4 tumorsPatient demographicsPrognostic factorsSLN positivityRetrospective reviewTumor characteristicsBreslow thicknessCutaneous melanomaT category
2022
103 JAK-STAT activation in anti-PD-1 therapy-associated granuloma annulare
Choi R, Wang J, Damsky W, Wang A, Galan A, Leventhal J. 103 JAK-STAT activation in anti-PD-1 therapy-associated granuloma annulare. Journal Of Investigative Dermatology 2022, 142: s18. DOI: 10.1016/j.jid.2022.05.038.Peer-Reviewed Original Research
2018
168 Nephrogenic systemic fibrosis
Galan A, Cowper S. 168 Nephrogenic systemic fibrosis. 2018, 557-558. DOI: 10.1016/b978-0-7020-6912-3.00168-3.Chapters
2017
Pathology and Molecular Features of Melanocytic Nevi and Melanoma
Galan A. Pathology and Molecular Features of Melanocytic Nevi and Melanoma. 2017 DOI: 10.1891/9781617052958.0002.Peer-Reviewed Original Research
2015
Nodular plaque in a cardiac transplant patient
Waldman A, Ezaldein H, Tomayko M, Galan A. Nodular plaque in a cardiac transplant patient. Journal Of The American Academy Of Dermatology 2015, 72: e111-e112. DOI: 10.1016/j.jaad.2014.12.037.Peer-Reviewed Original Research
2008
Reply
Galan A, McNiff J. Reply. Journal Of Cutaneous Pathology 2008, 35: 1164-1164. DOI: 10.1111/j.1600-0560.2007.00951.x.Peer-Reviewed Original Research
2006
GLI2 Does not Distinguish Between Basal Cell Carcinoma and Benign Adnexal Tumors
Galan A, Lazova R. GLI2 Does not Distinguish Between Basal Cell Carcinoma and Benign Adnexal Tumors. American Journal Of Dermatopathology 2006, 28: 230. DOI: 10.1097/00000372-200606000-00022.Peer-Reviewed Original Research